Teclistamab-Daratumumab in AL Amyloidosis
Part of paid clinical trials in Boston, Massachusetts.
- Sponsor
- Rajshekhar Chakraborty, MD
- Study ID
- NCT07110844
- Phase
- PHASE2
- Status
- Recruiting
Conditions
- Amyloid Light-chain Amyloidosis
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - 100 Years
- Healthy Volunteers
- Not accepted
Interventions
- Teclistamab — DRUGTeclistamab is a T-cell redirecting bispecific antibody (BsAb) targeting CD3 on T-cells and B-cell maturation antigen (BCMA) on plasma cells.
- Daratumumab and Hyaluronidase-fihj — DRUGDaratumumab is an monoclonal antibody that targets the CD38 protein on the surface of myeloma cells.
Study Details
The purpose of this study is to investigate whether teclistamab-daratumumab combination is effective and safe in AL amyloidosis. The study treatment is divided into cycles (C) and each cycle is 28 days (D). Study treatment is expected to last 6 months.
Key Dates
- First listed
- Aug 8, 2025
- Start date
- Nov 7, 2025
- Status verified
- Jul 2026
- Primary completion
- Oct 31, 2031
- Completion
- Oct 31, 2033
Study Design
- Enrollment
- 25 participants (estimated)
- Allocation
- NA
- Intervention model
- SINGLE_GROUP
- Primary purpose
- TREATMENT
Arms
- Experimental: Teclistamab-DaratumumabAll participants in this study will receive teclistamab and daratumumab.
Primary Outcome Measure
Hematologic Complete Response (Heme-CR) rate [ Time Frame: 6 months from treatment initiation ]
Central Contacts
- Central Nurse Navigator, RN(212) 342 5162
Locations (3)
| Facility | City | State | ZIP | Site coordinators |
|---|---|---|---|---|
| Boston Medical Center | Boston | Massachusetts | 02118 | - |
| Columbia University Irving Medical Center | New York | New York | 10032 | Rajshekhar Chakraborty, MD (PRINCIPAL_INVESTIGATOR) |
| Medical College of Wisconsin | Milwaukee | Wisconsin | 53226 | Anita D'Souza, MD, MS (PRINCIPAL_INVESTIGATOR) |
Find similar trials in Boston, MA
Related Studies
- Dose Schedule Study of BCMA Bispecific Antibody, Elranatamab, for Newly Diagnosed Immunoglobulin Light Chain (AL) AmyloidosisPHASE2 · Not Yet Recruiting · Case Comprehensive Cancer Center · Rochester, Minnesota